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A B S T R A C T   
Idebenone is a well described drug that was initially developed against dementia. The current literature widely 
portrays this molecule as a potent antioxidant and CoQ10 analogue. While numerous papers seem to support this 
view, a closer look indicates that the pharmacokinetics of idebenone do not support these claims. A major 
discrepancy between achievable tissue levels, especially in target tissues such as the brain, and doses required to 
show the proposed effects, significantly questions our current understanding. This review explains how this has 
happened and highlights the discrepancies in the current literature. More importantly, based on some recent 
discoveries, a new framework is presented that can explain the mode of action of this molecule and can align 
formerly contradictory results. Finally, this new appreciation of the molecular activities of idebenone provides a 
rational approach to test idebenone in novel indications that might have not been considered previously for this 
drug.   
1. Historical context 
Idebenone is a well-known compound, developed in the early 1980s 
by Takeda Pharmaceuticals against cognitive decline/dementia. To 
understand the results and discrepancies in the contemporary literature 
around this molecule, it is imperative to understand its history. In 1970s 
and 80s far less was known about the molecular events associated with 
cognitive decline and dementia. At the time, one prominent theory to 
explain the pathology of dementia was an age-dependent irreversible 
change of vascular structure and function [1,2]. In particular, decreased 
cerebral blood flow, oxygen utilization or blood volume [3], a 
dysfunctional cholinergic system that restricts blood flow [4,5] as well 
as plaque deposition [6] or disease states such as cerebral atherosclerosis 
[4] were thought to be involved. Since the vascular changes in the brain 
were linked to the presence of free radicals (i.e. reactive oxygen species 
(ROS)) and lipid peroxidation [7], lipophilic antioxidants such as Co-
enzyme Q and Vitamin E promised to provide therapeutic effects [8]. It 
was known that CoQ10 acts as a catalytic antioxidant when chemically 
reduced from the ubiquinone to the ubiquinol form to enable its anti-
oxidant activity. CoQ10 was also described to protect against lipid per-
oxidation in vitro [9] and in vivo [10]. However, CoQ10 is a large 
insoluble molecule with limited intestinal absorption and 
bioavailability. Therefore, a CoQ10 analogue with better 
pharmaco-chemical characteristics, but essentially the same molecular 
activity, was developed to a marketable drug that distanced the new 
molecule from the natural product CoQ10. Idebenone appeared ideal, 
with the same redox-active benzoquinone moiety as CoQ10, but 
increased solubility due to a significantly shorter lipophilic side chain 
that also contained a terminal hydroxyl group to increase polarity 
(Fig. 1). 
Based on an expectation that idebenone is a better CoQ10 analogue 
and therefore a better antioxidant to counteract the oxidative stress- 
induced vascular changes in dementia, multiple studies were pub-
lished that confirmed the expected outcomes. Studies on isolated mito-
chondria demonstrated antioxidant activity and decreased lipid 
peroxidation and mitochondrial swelling [11–13], which were also 
confirmed in vivo [14]. Similarly, idebenone prevented ROS-induced 
prostaglandin synthesis and platelet aggregation indicative of an anti-
oxidant function [15]. 
In line with the underlying hypothesis, idebenone was tested in a 
range of cerebrovascular disease models such as stroke [16,17], exper-
imental ischemia [18], hypertension [19,20], hypoxia [21] and also 
behavioural models that reflected the disease pathophysiology in de-
mentia [22,23]. Consistent with an anti-oxidant-driven increased 
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cerebral blood flow [24], perhaps also as a consequence of ameliorated 
cholinergic deficits [23,25,26], pre-clinical results with idebenone 
appeared to support the therapeutic approach. This was further 
strengthened in several pre-clinical models of dementia where idebe-
none not only showed potent cytoprotective activity [20,21] and 
improved neurotransmitter turnover [23,26,27], but also reduced 
neurological deficits [19], improved memory [17,18,28] and normal-
ised behaviour [22]. However, at a closer inspection, even these early 
studies appear contradictory. While micromolar idebenone doses for 
example were required to demonstrate activity on isolated mitochondria 
[13,29,30] only nano-molar concentrations were detected in the CNS 
and only for very short periods of time [16,31]. Up to this point, this 
discrepancy has not been widely appreciated or explained. In addition, 
only very limited information is available to what extent idebenone 
segregates into the different cellular compartments (i.e. cytoplasm, 
membranes, and mitochondria) and whether this distribution could be 
tissue specific and differ in vitro and in vivo. 
2. Chemical context 
Idebenone is a benzoquinone (Fig. 1), and like all quinones 
(including CoQ10) it can accept and donate electrons. It is this specific 
activity that forms the basis for the view that idebenone can act as an 
antioxidant and electron carrier in a cellular context. For quinones to be 
chemically reduced in cells and tissues, two principal pathways are 
available [32]. Reduction by a single electron can be performed by 
cellular reductases such as the p450 detoxification enzymes. However, 
this single electron reduction gives rise to an unstable semiquinone that 
produces superoxide and is therefore associated with significant 
toxicity. Given the many naturally occurring quinone compounds that 
organisms are exposed to, for example through the diet (i.e. Vitamin K) 
this possible source of toxicity is prevented in cells by a two-electron 
reduction mechanism. In the case of idebenone, this is done by NAD 
(P)H quinone oxidoreductase 1 (NQO1) that generates the stable hy-
droquinone form, which can be regarded as the active form of the 
molecule. This activated idebenone molecule can now donate electrons 
to detoxify radicals [32] as well as to the mitochondrial respiratory 
chain to aide ATP production [33,34]. These characteristics are sup-
ported by several reports that described idebenone toxicity and/or a lack 
of efficacy in test systems with low or absent NQO1 status [35]. It must 
be emphasized that NQO1 is part of the cells physiological response to 
stress and can be readily upregulated in many cell types and tissues via 
the Keap/Nrf2/ARE pathway [36], which in turn affects the biological 
activity of idebenone. In fact, idebenone itself was reported to upregu-
late NQO1 levels in vivo, which suggests that idebenone induces its own 
bioactivation system [37]. This begs the question: to what extent is 
idebenone a direct antioxidant? 
3. Is idebenone a direct antioxidant? 
Based on a large number of in vitro and in vivo studies, idebenone has 
been widely portrayed as a potent antioxidant [32,38], but is the evi-
dence really conclusive? Many studies have reported that bioactivated 
idebenone can effectively protect against oxidative stress in numerous 
different test systems, which appears to substantiate its antioxidant ac-
tivity. However, the interpretation of the results is heavily influenced by 
an expectation that idebenone acts as a direct antioxidant. It is undis-
puted that idebenone contains a redox-active quinone moiety that in 
principle could donate electrons to detoxify radicals [32]. However, 
there is in fact a scarcity of studies that succeeded to measure a direct 
antioxidant function of idebenone. Direct antioxidant function are best 
studied in cell free systems with defined mechanisms of ROS production, 
which differentiate the measured effects from the cellular environment 
with a multitude of potentially interfering redox reactions. In studies 
that aimed to formulate idebenone to increase its activity, high micro-
molar concentrations were required to measure direct antioxidant ef-
fects in cell-free systems [39–41], while other cell-free studies did not 
detect any antioxidant activity at all at concentrations of up to 600 μM 
[42]. Similarly, in isolated mitochondria micromolar concentrations 
were required for antioxidant activity, a process that is dependent on 
Fig. 1. Structural comparison of idebenone with 
CoQ10. In addition to the benzoquinone moiety that is 
shared by both molecules, the tail of CoQ10 contains 
ten isoprenyl (CH2–CH––C(CH3)–CH2) subunits, 
while idebenone contains 10 methylene (CH2) sub-
units and a terminal hydroxyl group. A two-electron 
reduction of idebenone by NQO1 generates the 
active hydroquinone form, while a one-electron 
reduction generates the unstable semiquinone. 
Figure was made using www.biorender.com.   
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complex II activity to reduce idebenone to the activated hydroquinone 
form [12,13]. The only exception we are aware of is a report where 
idebenone reduced glycerophosphate-induced oxidative species with an 
IC50 of 50 nM in mitochondria isolated from brown adipose tissue [43]. 
Why this isolated report shows effects of idebenone at these low con-
centrations is so far unexplained, but if the benzoquinone moiety of 
idebenone acted directly as an acceptor for the 
glycerophosphate-derived electrons, it could have prevented ROS for-
mation in the first place. Unfortunately, this report did not experimen-
tally differentiate between the possibility of reduced ROS production 
versus a direct radical scavenging function of idebenone. Apart from this 
study, there is general agreement that at least micromolar, sometimes up 
to millimolar idebenone concentrations, combined with a test system 
that converts idebenone to the hydroquinone form, are required to see 
any direct antioxidant activity [26,42,44]. In contrast to cell-free 
studies, the majority of studies that reported “antioxidant activity” in 
cell culture used extended preincubation times with idebenone, typi-
cally overnight or over several days despite the fact that idebenone 
penetrates cells within a few minutes [45–47]. Although the majority of 
studies used concentrations in the low micromolar range, some sur-
prisingly reported protective effects against ROS-induced toxicity at 
nanomolar concentrations [45,47] which are, unlike micromolar con-
centrations, drug concentrations that can be achieved in vivo. 
In fact, studies in rodents consistently reported antioxidant effects of 
idebenone [48–50], while only very low nanomolar concentrations in 
target tissues could be detected for only short periods of time [16,31, 
51]. In addition, idebenone produces fluctuating plasma concentrations 
due to its short half-life, without significant evidence of drug accumu-
lation in tissues after repeated dosing [16,31]. Although, data on ide-
benone tissue levels are not available for human patients, the 
pharmacokinetic characteristics of the compound in test animals are 
likely translatable to human patients based on reported plasma con-
centrations [52,53]. As these characteristics are clearly at odds with a 
direct and sustained antioxidant activity of idebenone, the obvious 
question is: How can idebenone protect against oxidative stress? 
Effective physiological antioxidant systems in cells and tissues 
regulate ROS levels to the advantage of the organism. These endogenous 
antioxidants are typically present in micromolar to millimolar concen-
trations [54,55], making it therefore questionable how any antioxidant 
that only reaches nanomolar tissue concentrations can exert significant 
effects in the presence of much larger quantities of numerous endoge-
nous antioxidants. To explain this contradiction, an amplification pro-
cess can be postulated, where small quantities of drug induce effects that 
are several magnitudes larger. In fact, several in vitro and in vivo studies 
suggest that idebenone appears to do exactly that. In a model of 
galactose-induced cataract formation idebenone reduced oxidative 
damage by increasing total endogenous tissue antioxidant capacity [56]. 
This increased antioxidant capacity by idebenone is likely the conse-
quence of an increased expression of a range of endogenous antioxidants 
such as superoxide dismutase (SOD), catalase, NAD(P)H quinone 
oxidoreductase 1 (NQO1), glutathione (GSH), and glutathione peroxi-
dase (GPx) [37,45,48,49,57], while also downregulating the 
superoxide-producing enzyme NOX2 [58]. Interestingly, some of the 
antioxidant genes reported to be activated by idebenone such as SOD, 
NQO1 and GPx are controlled by the transcription factor Nrf2. Consis-
tent with the activation of Nrf2-dependent genes, Nrf2 activation by 
idebenone was observed in fibroblasts from Friedreich’s Ataxia patients, 
although the effect was comparatively small [59]. While it is clear that 
idebenone requires NQO1 for its bioactivation, it is unclear if the 
idebenone-dependent activation of the Nrf2-NQO1 pathway occurs in all 
target tissues. It was therefore proposed to use idebenone in combina-
tion with other Nrf2-dependent NQO1-inducers to increase the thera-
peutic efficacy of idebenone in cells and tissues with low NQO1 levels 
[38]. 
Overall, the current data strongly suggest that, instead of being a 
direct antioxidant, idebenone increases the ability of cells to counteract 
oxidative stress by upregulating their physiological defence mechanisms 
and decreasing the production of oxidative radicals. However, there is 
significant doubt that protection against ROS-induced damage is the 
only molecular activity of idebenone that confers cytoprotection. 
4. Does idebenone improve mitochondrial function and 
metabolism? 
Several in vivo studies described protective effects of idebenone in 
different disease models without affecting oxidative stress. For example, 
idebenone protected brain function in a mouse model of Angelman 
syndrome without any evidence of antioxidant activity [60]. Similarly, 
in models of coronary syndrome, idebenone showed cardioprotective 
activity that was not associated with any antioxidant function but 
reportedly relied on an acute normalisation of mitochondrial respiration 
[61]; an activity that was previously described in vitro in the presence of 
dysfunctional complex I [33,34]. 
Based on the structural similarity between idebenone and CoQ10, it 
was always assumed that idebenone directly influences mitochondrial 
respiration and acts as a CoQ10 analogue. The fact that idebenone is not 
a CoQ10 analogue has been described in detail elsewhere [32] and is 
based on in vitro and in vivo data [62,63]. So, what is the evidence that 
idebenone affects mitochondrial function differently to CoQ10 and how 
does this activity protect mitochondrial function under pathological 
conditions? On the one hand, there is clear evidence that, unlike CoQ10, 
idebenone competitively inhibits complex I at higher concentrations 
(IC50 = 5.9 μM), while activating complex II-dependent respiration 
[64–66]. Furthermore, idebenone upregulates the glycerophosphate 
(G3PDH) shunt in isolated mitochondria in the presence of normal 
CoQ10 levels [66–68]. On the other hand, in line with its clinical use, 
idebenone (>10 μM) directly increased basal respiration in cell lines 
derived from mitochondrial disease patients with complex I deficiency 
[69]. 
How idebenone translates these changes to mitochondrial function 
into a therapeutic effect in vivo cannot, however, be explained by these 
activities. Similar to the notion of a direct “antioxidant” function, all 
direct effects of idebenone on mitochondrial function have been 
described for micromolar concentrations of the drug that are unlikely to 
be reached in the target tissues. How can this be reconciled with reports 
that nanomolar idebenone concentrations can alter brain energetics? In 
a LHON patient with the homoplastic 11,778 mtDNA mutation, P31-MRS 
studies indicated that idebenone reversibly improved bioenergetics in 
both muscle and brain [70]. Similarly, exposure of rats to idebenone 
significantly increased the respiratory control index (RCI) in brain 
mitochondria [71], which suggests that very low concentrations of 
idebenone can alter mitochondrial function in vivo, possibly by a similar 
mechanism to the described antioxidative activity involving altered 
gene expression. Primary hepatocytes isolated from idebenone-treated 
animals showed resistance to rotenone similar to cell lines cultured in 
vitro [33]. Interestingly, in this experiment the final treatment of ani-
mals with idebenone occurred 24 h before the cells were isolated, which 
implies that under these conditions idebenone was no longer present in 
the isolated cells [33]. This observation supports the hypothesis that 
transient exposure to idebenone activates a protective mechanism that 
persists beyond the time that the drug is present. In fact, there is some 
evidence that idebenone can not only upregulate mitochondrial copy 
numbers [72] but also affect the expression of respiratory complexes in 
vivo [60], which could counteract mitochondrial dysfunction to some 
extent. These effects alone, however, cannot easily explain the 
idebenone-dependent normalisation of mitochondrial function under a 
variety of pathological conditions such as oxidative damage [45,61], 
kinase inhibitors [73], mitochondrial toxins [33,34,68,74], the presence 
of metabolic toxins [75], hypoxia and reperfusion [21,49,61], amy-
loid-beta1-40 peptide [76] and different genetic defects [60,70,77]. 
Given the multitude of toxic stimuli that idebenone protects against, 
a single mitochondrial target is unlikely. Instead, it seems more likely 
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that idebenone activates one or several fundamental pathways that 
confer this broad protective effect. 
5. New insights 
Only recently, several reports provided a completely different view 
on the mode of action of idebenone. These new insights could finally 
explain to a significant extent the at times inconsistent and contradictory 
literature, as well as rationalise new indications for this molecule. 
5.1. Effect of idebenone metabolites 
One of the main conceptual difficulties is to explain how idebenone 
can be protective, despite its rapid metabolic conversion. Interestingly, 
idebenone metabolites themselves might have some therapeutic activ-
ity. At least for the first idebenone metabolite, QS-10, where the ter-
minal hydroxyl group of idebenone (Fig. 1) is oxidized to a carboxylic 
acid group, complex I bypass and CoQ10 substitution activity were re-
ported [78]. Both activities are surprising since QS-10 is so water soluble 
that is should not be able to repeatedly enter the mitochondria [79]. In 
fact, in previous experiments QS-10 was unable to be reduced by NQO1 
nor to restore ATP levels in the presence of complex I dysfunction in 
hepatocarcinoma cells [33]. At present it is unclear how these discrep-
ancies can be explained. Although, cell and tissue type differences could 
be responsible, it must be noted that the quinone concentrations used by 
both studies differed significantly. While the former study [78] used 50 
μM quinones (which were chemically reduced to compensate for the 
absence of NQO1 in the cells used), the latter used 5 μM for measuring 
the rescue of ATP levels. Intriguingly, protective effects by QS-10 were 
also observed in Zebrafish, where this metabolite was reported to be 
more protective against rotenone toxicity compared to idebenone which 
could indicate that in vivo effects are not necessarily dependent on 
chemical reduction [78]. Although cytoprotection is consistently re-
ported despite a rapid metabolism of idebenone [80], this does not 
support the protective activity of idebenone metabolites since it is un-
clear at present what idebenone concentrations and for what period of 
time are required to initiate cytoprotection. Therefore, future studies 
will have to investigate the potential bioactivity of idebenone metabo-
lites and their molecular targets in significantly more detail. 
In fact, direct molecular protein targets have only recently been 
confirmed for idebenone. Although idebenone acts as a selective 
PPARα/γ agonist [81], only a small effect was observed in vivo at 
micromolar concentrations in zebrafish larvae, with idebenone report-
edly sharing this activity with CoQ10 [81]. Since there is no evidence 
that idebenone itself can substitute for CoQ10 [32], its protective mode 
of action that sets it apart from CoQ10 must necessarily involve another 
molecular mechanism. 
5.2. Inhibition of p52Shc 
Recently, idebenone was reported to competitively inhibit the 
function of p52Shc [82], which acts as an adaptor protein required for a 
variety of molecular complexes. Most notably, p52Shc regulates sig-
nalling by protein tyrosine kinase receptors (PTK), such as the insulin 
receptor, where it binds to phosphorylated tyrosine residues at the 
cytoplasmic portion of the receptor. Idebenone was shown to bind to the 
phospho-tyrosine binding domain (PTB) of p52Shc, which dissociates it 
from the activated receptor [82]. Intriguingly, 
idebenone-p52Shc-binding was observed at low nanomolar concentra-
tions and thus could for the first time explain how idebenone exerts its 
protective effects at physiological concentrations. As part of this mo-
lecular activity, idebenone reportedly reduced growth factor-induced 
extracellular signal-regulated kinase (Erk) signalling, while simulta-
neously over-activating Akt kinase via the IP3-kinase pathway [74,82]. 
Akt is a well described “survival-kinase” and controls a range of sig-
nalling pathways [83] that increase general resistance against stress 
[84], hypoxia [85], and drug exposure [86], while increasing insulin 
sensitivity [87], altering cellular metabolism [88], reducing inflamma-
tion [89], increasing lipid metabolism [90] and modifying mitochon-
drial function [91]; and could therefore account for some of the 
pleiotropic protective effects observed with idebenone. 
5.3. Upregulation of Lin28A 
Meanwhile, another publication provided a complementary new 
insight towards the mode of action of idebenone with wide ranging 
consequences. In a preclinical rodent model of hypoxia-reperfusion- 
induced vision loss, idebenone led to the retinal expression of the 
RNA-binding protein Lin28A, which was shown to be responsible for the 
observed neuroprotection [92]. Lin28A is a highly conserved regulator 
of many cellular RNAs that fundamentally affect metabolism, ageing, 
stress response, cell survival and also increase tissue repair [93,94]. The 
positive effect of Lin28A on tissue regeneration is mediated by increased 
mitochondrial function, improved glucose metabolism, increased insu-
lin sensitivity, Akt activation and reduced autophagy [93,95,96]. Under 
physiological conditions, Lin28A is mostly expressed during embryo-
genesis but downregulated in postnatal tissues with the exception of 
stem cells and reproductive tissues. Since recombinant expression of 
Lin28A is used to generate induced pluripotent stem cells (iPSC) from 
adult tissues, it is tempting to speculate that an idebenone-dependent 
upregulation of Lin28A in adult tissue could induce some aspects of a 
stem cell-like phenotype associated with some regenerative capacity 
[93]. There is at least some evidence that idebenone can affect the fate of 
neural stem cells. While idebenone upregulated both neuronal (MAP2) 
and astrocytic (GFAP) markers in early neuronal progenitors, it down-
regulated MAP2 expression in neuronal stem cells and neural pro-
genitors [72]. At present, it is unclear if this activity also translates into a 
rejuvenation of neuronal tissue. In support of this hypothesis, idebenone 
restored cortical nerve growth factor (NGF) levels in aged rats to the 
levels found in young rats, which was associated with restored cognitive 
function [97]. 
Interestingly, Lin28A overexpression was recently reported to pro-
mote axon regeneration in postmitotic neurons in the CNS [98]. The 
Lin28A-dependent regeneration of adult retinal ganglion cell axons from 
the retina back into the optic nerve [98] is of particular interest with 
regards to the clinical experience with idebenone in Leber’s Hereditary 
Optic Neuropathy (LHON) patients [99]. Typically, response times in 
patients are slow, which is why the accepted consensus suggests to treat 
with idebenone for one year before deciding whether the drug is effec-
tive or not in a particular patient [100]. Neither restoration of mito-
chondrial function nor antioxidant function can explain the slow 
recovery typically seen in idebenone-treated LHON patients over several 
months. In contrast, axonal outgrowth, speculative as it might seem at 
present, would be consistent with the observed timelines of patient re-
sponses but at present there is no concrete experimental evidence for 
this possibility. It must be acknowledged that the effect of idebenone on 
Lin28A has only been reported by a single study [89]. Although, we 
could confirm this effect both in vitro and in vivo (unpublished obser-
vation), independent groups will have to reproduce and extend these 
observations to clarify if this effect is causally linked to the cytopro-
tection by idebenone. 
5.4. Influence of hypoxia 
One of the problems to conclusively demonstrate efficacy of idebe-
none in pre-clinical models as well as in patients remains a lack of 
consistency and especially a lack of measurable effects under normal 
physiological conditions. In this context, the upregulation of Lin28A by 
idebenone might also provide an answer to this problem since this effect 
seems strictly dependent on the prior presence of hypoxia-reperfusion 
injury [92]. This observation is in agreement with a large number of 
reports that demonstrated idebenone-dependent protection against 
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hypoxia and hypoxia-reperfusion conditions [21,61,101–103]. Hypoxia 
is associated with numerous pathologies and diseases, which could 
explain why idebenone appears to show protective activity only in some 
animal models of disease and certain patients, while in other pre-clinical 
models and healthy individuals idebenone does not appear to have any 
effects. For the first time, this dependence on hypoxia could also explain 
the lack of consistency in pre-clinical in vitro models. Cell culture for 
example is notorious for the possibility of varying levels of hypoxia 
[104]. In vitro, hypoxia is influenced by many determinants such as 
metabolic activity and the number of cells per culture vessel, well ge-
ometry (volume to surface ratio), incubator vibration, handling of cul-
tures, media age and preparation technique, which could therefore 
affect the activity of idebenone. The exact molecular details regarding 
just how the protective role of idebenone is controlled by hypoxia is 
unclear at present and requires further studies to delineate this 
interaction. 
A recent study supported the hypoxia-dependent activity of idebe-
none in a neuroinflammatory model. Idebenone, at nanomolar to low 
micromolar concentrations, was only protective under hypoxia- 
reperfusion conditions, while under normoxic conditions it was inef-
fective [58]. When we confirmed the protective activity of idebenone in 
a rodent model of acute colitis, increased protection by idebenone was 
detected in the distal compared to the proximal colon [37]. The fact that 
oxygenation of the proximal colon is higher compared to the distal colon 
[105] supports the hypothesis that localised hypoxia could be a deter-
minant for regional protection by idebenone within the same tissue. 
Future studies will need to investigate this possible connection in 
well-designed experiments to optimize the use of idebenone. Overall, 
p52Shc inhibition, Lin28A induction and a requirement for hypoxia 
provide a new theoretical framework to assess the suitability of idebe-
none in new indications. 
5.5. Impact on inflammation 
A growing body of evidence suggests that idebenone reduces 
inflammation in a variety of test systems such as lupus [106], neuro-
inflammation [58,74], ulcerative colitis [37], sepsis [107], 
nano-toxicity [108], atherosclerosis [48] and drug-induced inflamma-
tion [109]. This effect cannot be explained by antioxidant activity or a 
normalisation of energy supply alone. Instead, it was recently described 
that under hypoxia-reperfusion conditions, idebenone prevents the 
release of mtDNA and the subsequent activation of the inflammasome 
LNRP3, which enables idebenone to interfere with one of the earliest 
stages of the pro-inflammatory cascade [58]. It is important to note that 
inflammation is typically associated with hypoxia [110] and has a clear 
mitochondrial involvement [111], which suggests that inflammatory 
conditions could be clinically targeted with idebenone (Fig. 2). 
5.6. Impact on ER stress 
Inflammation is also tightly associated with the unfolded protein 
response [112] that is a characteristic physiological response to 
Fig. 2. Schematic representation of the interplay between hypoxia, mitochondrial dysfunction, oxidative damage, and inflammation. Figure was made using www. 
biorender.com. 
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endoplasmic reticulum (ER) stress [113] and is observed in a large 
number of diseases. Given the close interactions between ER, mito-
chondria and ROS, it could be expected that idebenone might also be of 
benefit to patients that display ER stress. In fact, there is some evidence 
that idebenone might be beneficial in Wolfram Syndrome (WS), where, 
idebenone induced progressive but subjective visual recovery in a WS 
patient [114]. Given that WS cells are regarded as a perfect model to 
study and treat ER stress [115], this observation paved the way to test 
idebenone in other models associated with ER stress. In a mouse model 
of chronic colitis that is based on ER stress in intestinal Goblet cells, we 
recently observed that idebenone effectively restored tissue integrity 
and reduced disease symptoms [116]. This effect was associated with 
the downregulation of the ER stress markers CHOP, XBP-1 and ATF-6 in 
the distal colon and a near complete suppression of pro-inflammatory 
cytokines [116]. 
6. Conclusion 
Overall, the idebenone-dependent activation of distinct signalling 
events that include inhibition of p52Shc, increased Lin28A expression, 
activation of Akt, and the subsequent transcriptional changes represent 
for the first time a convincing alternative to the long-held antioxidant 
hypothesis to explain the pleiotropic protective effects of idebenone in a 
large number of test systems (Fig. 3). Interestingly, the reported effects 
of Lin28A overexpression largely mirror the activities of p52Shc 
inhibition, such as Akt activation, reduced insulin resistance, altered 
metabolism, increased cytoprotection and changes to mitochondrial 
function. It is therefore tempting to speculate that both idebenone- 
induced events could be components of a shared pathway, which is 
the topic of ongoing studies. Based on a new understanding of the mo-
lecular activities and requirements of this drug, it can be expected that 
new indications for idebenone will be identified. 
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Fig. 3. Schematic representation of the current evidence how idebenone could influence several cytoprotective mechanisms simultaneously. Figure was made using 
www.biorender.com. 
N. Gueven et al.                                                                                                                                                                                                                                 
Redox Biology 38 (2021) 101812
7
Acknowledgements 
We would like to acknowledge the support of the University of 
Tasmania and Victoria University for the preparation of this manuscript. 
References 
[1] A.G. Herzog, T.L. Kemper, Amygdaloid changes in aging and dementia, Arch. 
Neurol. 37 (1980), https://doi.org/10.1001/archneur.1980.00500590049006. 
[2] H. Tachibana, J.S. Meyer, Y. Kitagawa, R.L. Rogers, H. Okayasu, K.F. Mortel, 
Effects of aging on cerebral blood flow in dementia, J. Am. Geriatr. Soc. 32 
(1984), https://doi.org/10.1111/j.1532-5415.1984.tb05850.x. 
[3] R.L. Grubb, M.E. Raichle, M.H. Gado, J.O. Eichling, C.P. Hughes, Cerebral blood 
flow, oxygen utilization, and blood volume in dementia, Neurology 27 (1977), 
https://doi.org/10.1212/wnl.27.10.905. 
[4] J. Parkes, C. Marsden, J. Rees, G. Curzon, B. Kantamaneni, R. Knill-Jones, et al., 
Parkinson’s disease, cerebral arteriosclerosis, and senile dementia: clinical 
features and response to levodopa, QJM: Int. J. Med. 43 (1974), https://doi.org/ 
10.1093/oxfordjournals.qjmed.a067377. 
[5] R.J. Marttila, U.K. Rinne, Dementia in Parkinson’s disease, Acta Neurol. Scand. 
54 (1976), https://doi.org/10.1111/j.1600-0404.1976.tb04375.x. 
[6] T. Miyakawa, S. Sumiyoshi, E. Murayama, M. Deshimaru, Ultrastructure of 
capillary plaque-like degeneration in senile dementia, Acta Neuropathol. 29 
(1974), https://doi.org/10.1007/BF00685258. 
[7] H. Demopoulos, E. Flamm, D. Pietronigro, M. Seligman, The free radical 
pathology and the microcirculation in the major central nervous system 
disorders, Acta Physiol. Scand. 110 (1980). 
[8] J. Clausen, Demential syndromes and the lipid metabolism, Acta Neurol. Scand. 
70 (1984), https://doi.org/10.1111/j.1600-0404.1984.tb00835.x. 
[9] A.a. Mellors, A. Tappel, The inhibition of mitochondrial peroxidation by 
ubiquinone and ubiquinol, J. Biol. Chem. 241 (1966). 
[10] S. Marubayashi, D. Kiyohiko, Y. Kazuo, K. Takashi, Changes in the levels of 
endogenous coenzyme Q homologs, α-tocopherol, and glutathione in rat liver 
after hepatic ischemia and reperfusion, and the effect of pretreatment with 
coenzyme Q10, Biochim. Biophys. Acta Gen. Subj. 797 (1984), https://doi.org/ 
10.1016/0304-4165(84)90375-1. 
[11] M. Suno, A. Nagaoka, Inhibition of brain mitochondrial swelling by idebenone, 
Arch. Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/0167-4943(89) 
90011-3. 
[12] M. Suno, A. Nagaoka, Inhibition of lipid peroxidation by a novel compound (CV- 
2619) in brain mitochondria and mode of action of the inhibition, Biochem. 
Biophys. Res. Commun. 125 (1984), https://doi.org/10.1016/0006-291x(84) 
91389-5. 
[13] M. Suno, A. Nagaoka, Inhibition of lipid peroxidation by idebenone in brain 
mitochondria in the presence of succinate, Arch. Gerontol. Geriatr. 8 (1989), 
https://doi.org/10.1016/0167-4943(89)90010-1. 
[14] M. Suno, M. Shibota, A. Nagaoka, Effects of idebenone on lipid peroxidation and 
hemolysis in erythrocytes of stroke-prone spontaneously hypertensive rats, Arch. 
Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/0167-4943(89)90012-5. 
[15] M. Suno, Z. Terashita, A. Nagaoka, Inhibition of platelet aggregation by 
idebenone and the mechanism of the inhibition, Arch. Gerontol. Geriatr. 8 
(1989), https://doi.org/10.1016/0167-4943(89)90013-7. 
[16] Y. Nagai, K. Yoshida, S. Narumi, S. Tanayama, A. Nagaoka, Brain distribution of 
idebenone and its effect on local cerebral glucose utilization in rats, Arch. 
Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/0167-4943(89)90008-3. 
[17] Y. Kiyota, K. Hamajo, M. Miyamoto, A. Nagaoka, Effect of idebenone (CV-2619) 
on memory impairment observed in passive avoidance task in rats with cerebral 
embolization, Jpn. J. Pharmacol. 37 (1985), https://doi.org/10.1254/jjp.37.300. 
[18] N. Yamazaki, T. Yomei, A. Nagaoka, Y. Nagawa, Beneficial effect of idebenone 
(CV-2619) on cerebral ischemia-induced amnesia in rats, Jpn. J. Pharmacol. 36 
(1984), https://doi.org/10.1254/jjp.36.349. 
[19] A. Nagaoka, M. Kakihana, K. Fujiwara, Effects of idebenone on neurological 
deficits following cerebrovascular lesions in stroke-prone spontaneously 
hypertensive rats, Arch. Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/ 
0167-4943(89)90003-4. 
[20] A. Nagaoka, A. Shino, M. Kakihana, H. Iwatsuka, Inhibitory effect of idebenone 
(CV-2619), a novel compound, on vascular lesions in hypertensive rats, Jpn. J. 
Pharmacol. 36 (1984), https://doi.org/10.1254/jjp.36.291. 
[21] Y. Kiyota, M. Miyamoto, A. Nagaoka, Protective effect of idebenone against 
hypoxia in mice, Arch. Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/ 
0167-4943(89)90006-x. 
[22] M. Miyamoto, A. Nagaoka, Effects of idebenone, a cerebral metabolism activator, 
on muricidal behavior in rats with raphe lesions, Pharmacol. Biochem. Behav. 27 
(1987), https://doi.org/10.1016/0091-3057(87)90579-x. 
[23] N. Yamazaki, M. Nomura, A. Nagaoka, Y. Nagawa, Idebenone improves learning 
and memory impairment induced by cholinergic or serotonergic dysfunction in 
rats, Arch. Gerontol. Geriatr. 8 (1989), https://doi.org/10.1016/0167-4943(89) 
90005-8. 
[24] A. Nagaoka, M. Suno, M. Shibota, M. Kakihana, Effects of idebenone on 
neurological deficits, local cerebral blood flow, and energy metabolism in rats 
with experimental cerebral ischemia, Arch. Gerontol. Geriatr. 8 (1989), https:// 
doi.org/10.1016/0167-4943(89)90002-2. 
[25] M. Kakihana, N. Yamazaki, A. Nagaoka, Effects of idebenone (CV-2619) on the 
concentrations of acetylcholine and choline in various brain regions of rats with 
cerebral ischemia, Jpn. J. Pharmacol. 36 (1984), https://doi.org/10.1254/ 
jjp.36.357. 
[26] A. Nagaoka, Y. Nagai, N. Yamazaki, M. Miyamoto, Y. Kiyota, Beneficial effects of 
idebenone on memory impairment in rats, Drug Dev. Res. 14 (1988), https://doi. 
org/10.1254/jjp.36.349. 
[27] S. Narumi, Y. Nagai, M. Kakihana, N. Yamazaki, A. Nagaoka, Y. Nagawa, Effects 
of idebenone (CV-2619) on metabolism of monoamines, especially serotonin, in 
the brain of normal rats and rats with cerebral ischemia, Jpn. J. Pharmacol. 37 
(1985), https://doi.org/10.1254/jjp.37.235. 
[28] N. Yamazaki, Y. Kiyota, Y. Take, M. Miyamoto, Y. Nagawa, A. Nagaoka, Effects of 
idebenone on memory impairment induced in ischemic and embolization models 
of cerebrovascular disturbance in rats, Arch. Gerontol. Geriatr. 8 (1989), https:// 
doi.org/10.1016/0167-4943(89)90004-6. 
[29] Y. Sugiyama, T. Fujita, M. Matsumoto, K. Okamoto, I. Imada, Effects of idebenone 
(CV-2619) and its metabolites on respiratory activity and lipid peroxidation in 
brain mitochondria from rats and dogs, J. Pharmacobio-Dyn 8 (1985), https:// 
doi.org/10.1248/bpb1978.8.1006. 
[30] I. Imada, T. Fujita, Y. Sugiyama, K. Okamoto, Y. Kobayashi, Effects of idebenone 
and related compounds on respiratory activities of brain mitochondria, and on 
lipid peroxidation of their membranes, Arch. Gerontol. Geriatr. 8 (1989), https:// 
doi.org/10.1016/0167-4943(89)90014-9. 
[31] H. Torii, K. Yoshida, T. Kobayashi, T. Tsukamoto, S. Tanayama, Disposition of 
idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and 
dogs, J. Pharmacobio-Dyn 8 (1985), https://doi.org/10.1248/bpb1978.8.457. 
[32] N. Gueven, K. Woolley, J. Smith, Border between natural product and drug: 
comparison of the related benzoquinones idebenone and coenzyme Q10, Redox 
Biology 4 (2015), https://doi.org/10.1016/j.redox.2015.01.009. 
[33] R.H. Haefeli, M. Erb, A.C. Gemperli, D. Robay, I.C. Fruh, C. Anklin, et al., NQO1- 
dependent redox cycling of idebenone: effects on cellular redox potential and 
energy levels, PloS One 6 (2011), https://doi.org/10.1371/journal. 
pone.0017963. 
[34] V. Giorgio, V. Petronilli, A. Ghelli, V. Carelli, M. Rugolo, G. Lenaz, et al., The 
effects of idebenone on mitochondrial bioenergetics, Biochim. Biophys. Acta 
Bioenerg. 1817 (2012), https://doi.org/10.1016/j.bbabio.2011.10.012. 
[35] S.M. Jaber, X.G. Shealinna, J.L. Milstein, J.W. VanRyzin, J. Waddell, B.M. Polster, 
Idebenone has distinct effects on mitochondrial respiration in cortical astrocytes 
compared to cortical neurons due to differential NQO1 activity, J. Neurosci. 40 
(2020), https://doi.org/10.1523/JNEUROSCI.1632-17.2020. 
[36] A.T. Dinkova-Kostova, W.D. Holtzclaw, R.N. Cole, K. Itoh, N. Wakabayashi, 
Y. Katoh, et al., Direct evidence that sulfhydryl groups of Keap1 are the sensors 
regulating induction of phase 2 enzymes that protect against carcinogens and 
oxidants, Proc. Natl. Acad. Sci. Unit. States Am. 99 (2002), https://doi.org/ 
10.1073/pnas.172398899. 
[37] S. Shastri, T. Shinde, S.S. Sohal, N. Gueven, R. Eri, Idebenone protects against 
acute murine colitis via antioxidant and anti-inflammatory mechanisms, Int. J. 
Mol. Sci. 21 (2020), https://doi.org/10.3390/ijms21020484. 
[38] S. Jaber, B.M. Polster, Idebenone and neuroprotection: antioxidant, pro-oxidant, 
or electron carrier? J. Bioenerg. Biomembr. 47 (2015) https://doi.org/10.1007/ 
s10863-014-9571-y. 
[39] L. Montenegro, M.N. Modica, L. Salerno, A.M. Panico, L. Crascì, G. Puglisi, et al., 
In vitro antioxidant activity of idebenone derivative-loaded solid lipid 
nanoparticles, Molecules 22 (2017), https://doi.org/10.3390/ 
molecules22060887. 
[40] H. Zhai, M. Cordoba-Diaz, C. Wa, X. Hui, H.I. Maibach, Determination of the 
antioxidative capacity of an antioxidant complex and idebenone: an in vitro rapid 
and sensitive method, J. Cosmet. Dermatol. 7 (2008), https://doi.org/10.1111/ 
j.1473-2165.2008.00370.x. 
[41] S.M. Cardoso, C. Pereira, C.R. Oliveira, The protective effect of vitamin E, 
idebenone and reduced glutathione on free radical mediated injury in rat brain 
synaptosomes, Biochem. Biophys. Res. Commun. 246 (1998), https://doi.org/ 
10.1006/bbrc.1998.8563. 
[42] I. Semsei, K. Nagy, I.Z.- Nagy, In Vitro Studies on the OH• and O2− • Free Radical 
Scavenger Properties of Idebenone in Chemical Systems, vol. 11, Archives of 
Gerontology and Geriatrics, 1990, https://doi.org/10.1016/0167-4943(90) 
90064-d. 
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Inhibition of glycerophosphate-dependent H2O2 generation in brown fat 
mitochondria by idebenone, Biochem. Biophys. Res. Commun. 339 (2006), 
https://doi.org/10.1016/j.bbrc.2005.11.035. 
[44] A. Mordente, G.E. Martorana, G. Minotti, B. Giardina, Antioxidant properties of 2, 
3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone (idebenone), 
Chem. Res. Toxicol. 11 (1998), https://doi.org/10.1021/tx970136j. 
[45] P. Lin, J. Liu, M. Ren, K. Ji, L. Li, B. Zhang, et al., Idebenone protects against 
oxidized low density lipoprotein induced mitochondrial dysfunction in vascular 
endothelial cells via GSK3β/β-catenin signalling pathways, Biochem. Biophys. 
Res. Commun. 465 (2015), https://doi.org/10.1016/j.bbrc.2015.08.058. 
[46] D.M. Fash, O.M. Khdour, S.J. Sahdeo, R. Goldschmidt, J. Jaruvangsanti, S. Dey, et 
al., Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial 
respiratory chain function and cytoprotection, Bioorg. Med. Chem. 21 (2013), 
https://doi.org/10.1016/j.bmc.2013.01.075. 
[47] S. Ranganathan, G.G. Harmison, K. Meyertholen, M. Pennuto, B.G. Burnett, K. 
H. Fischbeck, Mitochondrial abnormalities in spinal and bulbar muscular 
atrophy, Hum. Mol. Genet. 18 (2009), https://doi.org/10.1093/hmg/ddn310. 
[48] W. Jiang, H. Geng, X. Lv, J. Ma, F. Liu, P. Lin, et al., Idebenone protects against 
atherosclerosis in apolipoprotein E-deficient mice via activation of the Sirt3- 
N. Gueven et al.                                                                                                                                                                                                                                 
Redox Biology 38 (2021) 101812
8
SOD2-mtROS pathway, Cardiovasc. Drugs Ther. (2020), https://doi.org/ 
10.1007/s10557-020-07018-5. 
[49] N.A.A. Baky, Z.F. Zaidi, A.J. Fatani, M.M. Sayed-Ahmed, H. Yaqub, Nitric oxide 
pros and cons: the role of l-arginine, a nitric oxide precursor, and idebenone, a 
coenzyme-Q analogue in ameliorating cerebral hypoxia in rat, Brain Res. Bull. 83 
(2010), https://doi.org/10.1016/j.brainresbull.2010.07.004. 
[50] H. Yokoyama, N. Tsuchihashi, T. Ogata, M. Hiramatsu, N. Mori, An analysis of the 
intracerebral ability to eliminate a nitroxide radical in the rat after administration 
of idebenone by anin vivo rapid scan electron spin resonance spectrometer, 
Magnetic Resonance Materials in Physics, Biology and Medicine 4 (1996), 
https://doi.org/10.1007/BF01772013. 
[51] F.D. Heitz, M. Erb, C. Anklin, D. Robay, V. Pernet, N. Gueven, Idebenone protects 
against retinal damage and loss of vision in a mouse model of Leber’s hereditary 
optic neuropathy, PloS One 7 (2012), https://doi.org/10.1371/journal. 
pone.0045182. 
[52] J. Boni, A. Maugeri, G. Zingali, L. Ramelli, S. Gherardi, Steady-state 
pharmacokinetics of idebenone in healthy volunteers, Arch. Gerontol. Geriatr. 15 
(1992), https://doi.org/10.1016/0167-4943(92)90055-9. 
[53] C. Becker, K. Bray-French, J. Drewe, Pharmacokinetic evaluation of idebenone, 
Expet Opin. Drug Metabol. Toxicol. 6 (2010), https://doi.org/10.1517/ 
17425255.2010.530656. 
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